Register Log-in Investor Type

Healthcare News

This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.

15 Feb 2019
BB Healthcare announces result of issue

BB Healthcare has “another successful year”

BB Healthcare Trust has announced its annual results for the year ended 30 November 2018. During what the trust’s chairman, Professor Justin Stebbing, describes as “another successful year”, the trust provided Nav and share price total returns of 24.0% and 21.6% respectively. These returns are ahead of the MSCI World Healthcare Index, which it says […]

24 Jan 2019
Primary Health and MedicX to merge

Primary Health and MedicX to merge

Primary Health and MedicX to merge – The boards of Primary Healthcare Properties (PHP) and MedicX Fund have reached agreement on the terms of a recommended all-share merger between MedicX and PHP, which is intended to be structured as  PHP acquiring the entire issued and to be issued share capital of MedicX. Under the terms of […]

23 Jan 2019

WWH opens new positions in Takeda and Novartis  

WWH opens new positions in Takeda and Novartis Orbimed-managed Worldwide Healthcare Trust (WWH) has disclosed new substantial shareholdings in Takeda – the Japanese pharmaceuticals group that has just completed a takeover of Shire Pharmaceuticals – and Novartis, according to an analysis by Marten & Co. The shareholding in Takeda appears in third place and accounts for […]

23 Jan 2019

BPCR gains windfall profit on Tesaro loan

BPCR boosted by windfall profit on Tesaro loan BioPharma Credit (BPCR), the LSE-listed investment vehicle that specialises in providing loans to biotech companies, is to receive a windfall profit from the early repayment of a $500m loan (of which it provided 64%) to Tesaro last year. This follows the completion of the acquisition of Tesaro, […]

16 Jan 2019

QuotedData join the Master Investor Show 2019 main stage line-up

QuotedData join the Master Investor Show 2019 main stage line-up – QuotedData is, once again, a key sponsor for the Master Investor Show. Edward Marten, QuotedData’s CEO, shall join the Main Stage line-up on Saturday, 6 April, at London’s Business Design Centre. We’d love to see as many of you as we can at the event. […]

20 Dec 2018

Polar Capital Global Healthcare let down by widening discount

Polar Capital Global Healthcare let down by widening discount – Polar Capital Global Healthcare reports that its NAV rose by 19.8% over the year end of September 2018 on a total return basis, ahead of its benchmark, the MSCI ACWI Healthcare Index, which returned 17.2% over the same period. However, a widening in the discount to NAV […]

29 Nov 2018

BB Healthcare announces result of issue

BB Healthcare announces result of issue- BB Healthcare Trust plc (BBH) announced today that they have successfully raised gross proceeds of approximately £46.3 million from an initial placing, offer for subscription and intermediaries offer of ordinary shares. The net proceeds of the initial issue are approximately £45.4 million. They raised the money through the issue […]

30 Oct 2018

International Biotechnology benefits from narrowing discount

International Biotechnology benefits from narrowing discount – International Biotechnology has reported that, over the year ended 31 August 2018, its NAV laggeded the NASDAQ Biotechnology Index (NBI) a little, returning 8.6% versus the NBI return of 10.1%. A narrowing discount meant that shareholders saw a total return of 13.7%, however. The biotech sector outperformed the UK equity market over […]

23 Oct 2018

Caledonia selling Choice Care Group

Caledonia selling Choice Care Group – Caledonia Investments is selling Choice Care Group, a provider of residential and supported living services for people with learning disabilities and mental health conditions, to iCON Infrastructure Partners, IV L.P., a fund advised by iCON Infrastructure LLP, an independent infrastructure investment group with approximately EUR2.5bn of assets under management. Choice was […]

20 Sep 2018

BioPharma Credit extends loan to Amicus

BioPharma Credit extends loan to Amicus – BioPharma Credit (BCPR) has entered into a $150m, five-year loan agreement with Amicus Therapeutics, a US-based biotech focused on rare disease. The senior secured loan will have a 2.0% additional consideration and bears interest at Libor plus 7.5% subject to a floor of 1% and certain caps. The loan is interest […]

10 Sep 2018

Malin achieves small increase in fair value of investments

Malin achieves small increase in fair value of investments Dublin-listed biotech VC investor Malin (ISE:MLC) achieved a marginal increase in the fair value of its investment portfolio in the first half of 2018, with gains on its four largest investments set against write-downs on smaller ones. This fair value, which was struck in accordance with […]

03 Sep 2018

IBT-investee Sangamo set to disclose gene edited drug data

IBT-investee Sangamo set to disclose gene edited drug data US biotech Sangamo Therapeutics (Nasdaq: SGMO), a mid portfolio but recently enlarged holding for the UK-listed International Biotech Trust (IBT),  is set to report the first clinical data from its SB-913 in vivo genome edited therapeutic for  Hunter syndrome,  at a scientific conference later this week. Sangamo will […]

03 Sep 2018

AZN lupus setback shifts focus to J&J/Lilly drugs

AZN lupus setback shifts focus to J&J/Lilly drugs The failure last week of the first of two Phase III studies of an AstraZeneca monoclonal antibody in systemic lupus erythematosus (SLE) – and the now assumed lower prospects for success in the second almost identical trial – looks as if it will reduce yet further the industry’s […]

30 Aug 2018

IP Group-backed Genomics raises £25m in a Series B

IP Group-backed Genomics raises £25m in a Series B Genomics plc, a University of Oxford spin-out backed by UK-based healthcare/tech VC investor IP Group (LSE: IPO), has closed a £25.0m Series B financing round led by the major US biotech, Vertex Pharmaceuticals.  Woodford Investment Management – manager of the Woodford Patient Capital Trust (WPCT) – Invesco Perpetual, Oxford […]

28 Aug 2018

Trust favourite Alnylam gains on competitor data

Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) gained more than 16% yesterday after the presentation of ostensibly highly positive clinical trial data on one of its key competitors at a scientific meeting. Alnylam is held by several of the sector’s specialist investment trusts including Biotech Growth (BIOG, 3.6% of NAV) and BB Biotech (BBB, 3.6% of NAV) […]

28 Aug 2018

BB-backed Ionis hit as FDA rejects Waylivra

BB-backed Ionis hit as FDA rejects Waylivra Shares in Ionis Pharmaceuticals (Nasdaq: IONS), a key shareholding for BB Biotech (10.9% of NAV) and several other specialist investment vehicles, fell by more than 12% after hours yesterday, after the FDA issued a complete response letter (CRL) – effectively a rejection – of its new drug application for Waylivra (volanesorsen). The […]

22 Aug 2018

Trust favourite Gilead gears up for filgotinib RA Phase III data

Trust favourite Gilead gears up for filgotinib RA Phase III data Gilead Sciences, a widely held stock among biotech investment trusts and a top 10 holding for BB Biotech (BBB, 5.1% of NAV) and Biotech Growth Trust (BIOG, 3.9%), is expected  to report top-line results from two trials involving its JAK 1 selective inhibitor filgotinib in rheumatoid arthritis (RA) and in ankylosing […]

20 Aug 2018

BB-backed Ionis approaches key regulatory events

BB-backed Ionis approaches key regulatory events Ionis Pharmaceuticals (Nasdaq: IONS), a key shareholding for BB Biotech (10.9% of NAV) and several other specialist investment vehicles, is approaching a number of important regulatory events. In particular, these include the outcome of the FDA review for Waylivra, which has a deadline at the end of this month. Waylivra has been developed […]

16 Aug 2018

WPCT avoids losses on Woodford backed Abzena

WPCT avoids losses on Woodford-backed Abzena Woodford Investment Management will have to take a second painful hit on one of its major biotech investments in less than a week, after the UK-based drug discovery services company Abzena agreed to a low-ball private equity takeout today after seeing a sustained share price decline.  This deal follows the […]

16 Aug 2018

IBT adds to Celgene, reduces Neurocrine in July rejig

IBT adds to Celgene, reduces Neurocrine in July rejig International Biotechnology Trust (IBT) appears to have boosted its shareholding in Celgene – which has risen by one place and ~ two NAV  percentage points to become its top investee company, as part of a rejig of its largest investments in July. According to the trust’s latest […]

14 Aug 2018

Alnylam receives expected FDA ok for Onpattro

Alnylam receives expected FDA ok for Onpattro Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) received its  first FDA approval late on Friday for Onpattro (patisiran) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. However, the FDA did not allow a broader label that included patients with cardiomyopathy (CM), leading to […]

10 Aug 2018

Woodford finally closes chapter on failed Vernalis investment

Woodford finally closes chapter on failed Vernalis investment Neil Woodford’s eponymous Patient Capital Trust (WPCT) will have to look forward to receiving just £1.8m for the 30.6m shareholding – acquired in 2015 for £18.5m – in Vernalis, the UK biotech whose failed endeavour to break into the US cough/cold market led to it being put up […]

10 Aug 2018

Syncona remains at high premium and highly geared to Autolus

Syncona remains at high premium and highly geared to Autolus Syncona (SYNC)‘s shares have been the second best performer this year among the 14 biotech investment trusts monitored by Marten & Co, rising by 24.5% in the first seven months to end July. However, the trust’s NAV has only gained 8.7% in the period and […]

06 Aug 2018

Trust favourite Alnylam approaches key FDA decision

Trust favourite Alnylam approaches key FDA decision Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq:ALNY) should find out later this week whether the FDA will grant approval to its first product, Onpattro (patisiran), for hereditary transthyretin-mediated amyloidosis (or hATTR). In this case, unusually, there is relatively little concern that Onpattro may not receive US approval and the […]

06 Aug 2018

IBT backed Regeneron teams up with Bluebird on T cell cancer therapies

IBT backed Regeneron teams up with Bluebird on T cell cancer therapies US top tier biotech Regeneron Pharmaceuticals (NASDAQ: REGN) is to make a $100m equity investment at a 59% premium in the gene therapy pioneer Bluebird Bio, as part of a  newly established collaboration to develop and commercialise novel immune cell therapies for cancer. Regeneron is […]

06 Aug 2018

Arix leads first VIPE into Pharmaxis

Arix leads first VIPE into Pharmaxis LSE-quoted life science investor Arix Bioscience (ARIX) is to acquire an 11% interest in Pharmaxis (ASX: PXS) in its first VIPE or venture investment in public equity. Arix led a A$24m placing in the Australian biotech, in which it will invest A$14.2m for a 11% holding. This will mean the […]

03 Aug 2018

Tekla Healthcare top specialist fund performer in July

Tekla Healthcare top specialist fund performer in July Tekla Healthcare Opportunities, a  US closed end fund that invests largely in US large cap pharma and biotech, saw the best investment performance of the 14 specialist biotech specialist investors monitored by Marten & Co, in terms of its sterling-adjusted NAV performance for the month of July. Switzerland’s BB […]

03 Aug 2018

Trust favourite Neurocrine’s shares rise on strong Ingrezza report

Trust favourite Neurocrine’s shares rise on strong Ingrezza report Neurocrine Biosciences (Nasdaq: NBIX),  the US biotech that is the largest single holding for International Biotechnology Trust (IBT, 5.5% of NAV) and second largest for BB Biotech (BBB.S, 8.9% of NAV), has seen its share rise by more than 15% this week on the back of a strong […]

03 Aug 2018

Arix remains highly geared to Autolus value

Arix remains highly geared to Autolus value Arix Bioscience’s 8% investment in Autolus Therapeutics (Nasdaq: AUTL), the recently floated second-generation CAR-T company, now accounts for more than half of the value of its investments, some 25% of its NAV and almost 30% of its stockmarket value, according to calculations by Marten & Co. Arix is by far […]

02 Aug 2018

HBM sees best share price performance in YTD period

HBM sees best share price performance in YTD period London-listed HBM Healthcare (HBMN) recorded the best share price price performance so far this year of the 14 biotech specialist investment trusts monitored by Marten & Co, with a 25% rise in the seven months to end July. HBM’s share price outstripped growth in NAV, which […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…